The individual risk of ischemia or heart failure consequences should guide the treatment choice because sodium/glucose cotransporter-2 (SGLT-2) inhibitor therapy also lowers CV events (with impact predominantly driven by a reduction in heart failure complications). Here, SLC5A2 is linked to heart failure.